Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lactobacillus Farciminis and Hyperalgesia

This study has been completed.
Sponsor:
Information provided by:
Lallemand SAS
ClinicalTrials.gov Identifier:
NCT00852865
First received: February 25, 2009
Last updated: April 30, 2009
Last verified: April 2009

February 25, 2009
April 30, 2009
February 2009
April 2009   (final data collection date for primary outcome measure)
Measurement of the mchanical pain threshold in primary and secondary areas by using a punctate stimulus. [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00852865 on ClinicalTrials.gov Archive Site
Measurement of cutaneous temperature of hyperalgesia areas [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Lactobacillus Farciminis and Hyperalgesia
Effect of a Dialy Consumption of a Probiotic (Lactobacillus Farciminis) on Hyperalgesia in Response to Thermal Stimulation

We want to analyse a possible effect of o dialy consumption of Lactobacillus farciminis on a hyperalgesia on response to thermal stimulation. A comparaison of results before and after three weeks of treatment will be made.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Inflammation
  • Pain
  • Drug: Lactobacillus farciminis
    1 capsule per day. Each capsule containing 4*109 CFU
  • Drug: Placebo
    1 capsule per day
  • Experimental: 1
    24 healthy volunteers consuming L.farciminis during three weeks
    Intervention: Drug: Lactobacillus farciminis
  • Placebo Comparator: 2
    24 healthy volunteers consuming placebo during three weeks
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
April 2009
April 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy volunteers

Exclusion Criteria:

  • consumption of yogurts
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00852865
HN 08-17, 2008-A01380-55
No
Henri DURAND, LALLEMAND SAS
Lallemand SAS
Not Provided
Principal Investigator: Claude DUBRAY, Professor CPC/CIC-INSERM 501
Lallemand SAS
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP